ArticleJournal of nanobiotechnology2026
Dual induction of tissue-resident T and B cell immunity for broad influenza protection with a nanofiber-VLP vaccine.
Article in Journal of nanobiotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
Abstract
Respiratory pathogens pose significant global health challenges, with current vaccines often failing to prevent viral replication at mucosal entry points. To address this, we developed an adjuvant-free intranasal nanovaccine (NP@HA-VLP-Q11) by integrating SpyTag/SpyCatcher-mediated antigen multimerization on virus-like particles (VLPs) with self-assembling Q11 nanofibers. This vaccine leverages the ability of Q11 to induce both humoral and cellular immunity without requiring supplemental adjuvants or eliciting local inflammation to co-deliver a conserved nucleoprotein (NP) CD8+ T cell epitope and influenza hemagglutinin stem domain (miniHA) VLPs. In mouse models, we show that NP@HA-VLP-Q11 elicits systemic neutralizing antibodies and lung-resident memory T cells (TRMs) and B cells (BRMs) that are maintained for at least 12 weeks after immunization and expand rapidly upon heterologous H9N2 challenge. Importantly, intranasal immunization with NP@HA-VLP-Q11 conferred immunity and cross-protection against heterologous influenza strains that were preserved for at least 12 weeks. The dual induction of TRMs and BRMs offers immediate humoral protection and sustained cellular immunity at the infection site, mimicking natural viral exposure while avoiding replication risks. These findings demonstrate the potential of self-assembling nanomaterials combined with stabilized multimerized antigens in VLPs to create next-generation vaccines for broad, broad and effective protection against respiratory pathogens.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.